[A case of thymic carcinoma responding to combination chemotherapy with nedaplatin, etoposide, and ifosfamide].
We described a case of thymic carcinoma that responded remarkably to combined chemotherapy with etoposide (ETP), ifosfamide (IFO) and nedaplatin. A 68-year-old woman was admitted to our hospital because of hoarseness and dysphasia. Chest computed tomographic (CT) scans showed an anterior mediastinal tumor. Using CT-guided needle biopsy, the diagnosis was squamous cell type of thymic carcinoma. We gave her modified VIP therapy with ETP, IFO and nedaplatin. The tumor contraction response was evident after 3 courses of treatment. This case suggested that nedaplatin may be one of the promising agents for thymic carcinoma chemotherapy.
Kato
Daisuke
D
Dept of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences.
Achiwa
Hiroyuki
H
Sato
Shigeki
S
Bessho
Yuji
Y
Shimizu
Shigeki
S
Hattori
Noriko
N
Maeda
Hiroyoshi
H
Niimi
Takashi
T
Oguri
Tetsuya
T
Ueda
Ryuzo
R
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D013953:Thymus Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D014057:Tomography, X-Ray Computed
D009944:Organoplatinum Compounds; D005047:Etoposide; C053989:nedaplatin; D007069:Ifosfamide